

# We are Granules

Over the past four decades, we have grown from single paracetamol manufacturing facility to a multi-faceted global pharmaceutical company, delivering safe, cost-effective, and high-quality medicines. Strategic partnerships, particularly in the United States, and investments in research and development have helped us expand our product offerings to include finished dosages (FDs) and extend operations across India. Since inception, our actions have aligned with our commitments, embedding responsible practices at every stage from design through delivery.

6,525+

10

State-of-the-art manufacturing facilities 300+

Global customers across 80+ countries



Triton opened its second

Incorporated Granules India

Established our first PFI facility at Jeedimetla

**Triton Laboratories** was formed to produce Paracetamol API at our Bonthapally facility in Hyderabad

manfucturing facility at Jeedimetla to produce multiple APIs

**Private Limited** 

Established API R&D facility in Pragathi Nagar | Acquired Auctus Pharma - an API manufacturing facility with regulatory approvals

Received US FDA approval for our first Abbreviated New Drug Application (ANDA)

2008

Entered the Finished Dosages segment

2005

Built a new Paracetamol plant in Bonthapally, Hyderabad

Set up the largest single

manufacturing site for a

multi-unit pellet system

facility at Gagillapur

2003

Set up a new largevolume PFI facility in Gagillapur | Set up wholly-owned subsidiary, Granules USA, for marketing in the US

Became a listed company following an IPO at the Hyderabad Stock Exchange

Set up GPAK, a ~80,000

Set up a wholly-owned subsidiary in the US | **Granules Pharmaceuticals** began focusing on formulation R&D to forward integrate APIs

Laid the foundation for our Oncology API and OSD plant and a multiple product API plant in Visakhapatnam

Entered the front-end business for the sale of Rx Products in the US under the GPI label

sq. ft. packaging facility with four packaging suites and a warehousing facility | Established new purpose, mission, and values

Granules Life Sciences (GLS), with a planned FD capacity of 10 bn dosages, successfully commenced operations | Granules CZRO pilot plant commenced operations















## **Our Sustainability Journey**

FY 23-24 marked another crucial milestone in our journey of sustainable value creation. Over the years, we have achieved remarkable progress, and now we are harnessing our solid foundations to move closer to our vision.

- Recognized by CII for implementing 'Environmental Best Practices' at the Gagillapur plant
- Set a target of Zero Liquid Discharge (ZLD), Zero accident zone, and zero occupational health hazard status
- Conducted Hazard Analysis and Risk Assessment (HARA) for each manufactured product

- Successful completion of the Social Accountability Audit for the Gagillapur plant
- Green initiatives through investments in the ZLD at Bonthapally and the Effluent Treatment Plan at Gagillapur

- Initiated sourcing of electricity from solar power plants
- Supported local suppliers by sourcing 50%-55% from Telangana

Creation of a sustainability team to execute a focused ESG plan  Foray into Green Molecules Platform through Investment in CZRO Subsidiary

 Conducted materiality assessment for the first time and identified 13 ESG material topics

ty rst B ESG





000

2008 2013 2014 2017 2018 2019 2020 2021 2022 2023

The Bonthapally facility received the ISO 14001 certification for environmental management and the OHSAS 18001 certification for occupational health safety systems

- Set a compelling vision to empower significant number of individuals through Pharma Pathashala
- Launched a Self- Directed Team (SDT) program across manufacturing units to nurture skill development

Achieved reduction of solid waste generation and specific water consumption by 27% and 23% at Bonthapally API facility

Initiated Scope-1 & 2 GHG emission inventorization

- Conducted comprehensive GHG Inventorization across value chain including subsidiaries
- Submission of our SBTi net zero commitment
- United Nations Global Compact (UNGC)
   Partnership Established
- Completed PCF analysis for 65% of sales
- Advanced supplier sustainability program

See Sustainability Data Summary for full metrics and methodology.

1

- Achieved SBTi validation and approval for both near-term and long-term goals. Aligned with the 1.5°C pathway towards net zero by 2050 or sooner
- Achieved 1 MW on-site rooftop solar installation at Gagillapur Unit
- Achieved 69% Renewable Energy share through PPA, Rooftop Solar and I-RECs



27% reduction in waste to landfill





2050 TARGETS (co.)

Achieve Net Zero emissions

2050

2024

2027

2030

2032

#### Scope 1

- ▶ Demand-side Initiatives Area: Boiler Plant Optimization | Condensate Recovery
- Supply-side Initiatives Area: Switching from Coal to Biomass Boiler

#### Scope 2

STRATEGY

- Demand-side Initiatives Area: Chiller Plant Optimization | Pumping Optimization |
   Air Compressor Optimization
- ▶ Supply-side Intiatives Area: Renewable Energy through PPA & Group Captive

#### **Across Value Chain**

Supplier Sustainability Program to work with supplier to decarbonize value chain |
 Supplier Mix optimization | Green and sustainable sea cargo

#### **Eco Scale in Product Development**

Optimized resource utilization | Incorporating circularity in process development

#### **Green Molecule Platform**

- 24x7 Carbon free energy: Renewable Energy plus Battery storage
- Green molecules such as Green Hydrogen, Green ammonia
- Green chemicals for Pharmaceuticals (KSM/Advanced intermediates starting with raw material for Paracetamol and Metformin)

#### **Green Chemistry Platform**

- Enzymatic bio catalysis
- ▶ Flow & continuous manufacturing
- Granules Eco scale

#### **Sustainable Formulations**

- Solvent and polymer free formulations
- Plant based excipients
- Water efficient manufacturing
- Biodegradable and sustainable packing














### $\triangle$

## **Our Products**


We have a diverse portfolio of products across three main business segments. Our top three medicines are the largest molecules by volume in the Oral Solids category and rank among the top 10 on the WHO list of essential medicines.

### **Business Segments**










# Active Pharmaceutical Ingredients (API)





- Our FD portfolio includes Tablets, Caplets,
   Press-fit Capsules, blister packs, and bottles
- At our Gagillapur facility, we produce rapidand extended-release tablets, utilizing advanced automation, durable equipment, and robust manufacturing systems
- We have 92 approved ANDAs and Dossiers across US, Europe, Canada, UK and Rest of the world
- We specialize in large-scale PFI production with a 6-ton batch capacity at our Jeedimetla and Gagillapur facilities
- Our efficient process enables direct transfer from drums to hoppers, establishing us as a global PFI supplier
- We produce high-volume APIs like Paracetamol, Metformin, Guaifenesin, and Methocarbamol with a focus on quality and affordability
- With dedicated R&D efforts to expand our API portfolio, we have added products across categories, including anti-hypertensives, antihistamines, anti-infectives, analgesics, anti-coagulants, anti-fibrotic and platelet inhibitors













LATAM

### $\triangle$

## Catering to a Global Customer Base

We have established a strong global presence, Supplying over 60 molecules to more than 300 customers across 80 countries. With operations in India and the US, supported by four R&D centers in India, we drive innovation, scale, and efficiency, making Granules the preferred partner for leading pharmaceutical companies and retailers across the US, EU, UK, and other key markets.



Ms. Priyanka Chigurupati
Executive Director

At Granules, we recognize that achieving sustainability in our industry demands a comprehensive approach encompassing the entire value chain. While the pharmaceutical sector has made notable strides in reducing Scope 1 and Scope 2 emissions - those stemming directly from internal operations, these account for only a small fraction of our overall carbon footprint. The bulk of emissions, over 80%, arises from Scope 3 sources within the supply chain, a critical area that demands increased focus and action as we work toward the goals of the Paris Agreement. Granules is committed to supporting our customers in addressing these challenges and meeting their climate goals.

By embedding sustainable practices into every stage of our operations, from efficiency measures and renewable energy adoption to sustainable product development and manufacturing, culminating in our long-term vision of green molecules through our CZRO subsidiary, we are embracing green science for our customers to reduce their Scope 3 emissions and achieve meaningful climate milestones.

Trust-based partnerships are central to our philosophy, fostering collaboration and innovation to drive shared success. Together, we are shaping a future where sustainability is fundamental to every interaction, advancing toward a greener, more responsible world.



	Manufacturing Units	Capacity	Regulatory Approvals
API	Bonthapally, Telangana Jeedimetla, Telangana Vizag (Unit IV), Andhra Pradesh Vizag (Unit V), Andhra Pradesh Bonthapally II (API Intermediate)	34,560 TPA 4,800 TPA 380 KL 15 KL 61.5 KL	US FDA, EDQM, WHO, COFEPRIS, INFARMED US FDA, EDQM, COFEPRIS, WHO, CDCSO US FDA, KFDA, EU GMP, WHO GMP, EDQM EU GMP
PFI	Gagillapur Jeedimetla, Telangana	23,200 TPA 1,440 TPA	US FDA, COFEPRIS, TGA, MCC, INFARMED WHO GMP, COFEPRIS, INFARMED
FD FD	Gagillapur Virginia, USA Vizag (Unit V) Granules Life Sciences (GLS)	26.8 bn 1.5 bn 1.1 bn 2.5 bn (Phase-1)* 7.5 bn (Phase-2)#	US FDA, MCC, COFEPRIS, TGA, INFARMED US FDA, DEA EU GMP
Packaging	Virginia, USA	2 OTC lines and 1 Rx line	US FDA

<sup>\*</sup> Phase-1: Annual capacity by Mar-2025













% as share of Revenue

Note: Map not to scale.

<sup>#</sup> Phase-2: Annual capacity by 2026



## Awards & Recognitions

2024



#### BW PharmaWorld Person of the Year Award 2024

Granules India's Chairman and Managing Director honoured for his exemplary leadership and transformative contributions to the pharmaceutical industry 2024



#### Golden Peacock Awards – Winner of Sustainability 2024

Recognised for outstanding contributions to sustainability in business practices

2024



#### **ET RE Pharma Awards**

Awarded for excellence in contribution towards sustainability within the pharmaceutical industry

2024



#### CII 25<sup>th</sup> National Award for Excellence in Energy Management 2024

Recognised for excellence in energy efficiency and sustainable energy management practices 2023







Granules India Limited (Gagillapur) received these prestigious awards for their innovative enhancements to the batch release system, which reduced errors and cycle times since 2017





2023



#### Future Ready Organization

Granules India Limited was honored with the prestigious Economic Times Future Ready Organization Award, a testament to our commitment to innovation and preparedness for the future

2023



#### TSREDCO Awards TSECA 2023

Received the Gold from Telangana State Energy Conservation Awards under Large Scale Industry category 2023



### Most Trusted Brands of India 2023

Recognized for exceptional trust and reliability in delivering products and services

2023



#### IGBC Green Factory Buildings – Crusader of Sustainability

Honored for Granules Life Sciences Limited's commitment to sustainable factory operations 2022



#### Gold and Silver Winner at the 10<sup>th</sup> Cll National Poka-Yoke Competition

Awarded for excellence in implementing quality control and error-proofing manufacturing processes



## Partnerships, Collaborations and Ratings

#### Commitments



#### LACE TO ZERO

Our climate targets covering Near-term, Long-term, and Net Zero goals (2050 or sooner), aligned to 1.5°C pathway, have been validated and approved by SBTi & aligned with RACE TO ZERO

#### **WE SUPPORT**



Committed for UNGC 10 Principles of Human rights, Labor, Environment, and Anti-corruption



Granules Gagillapur unit has cleared the C-TPAT (Customs Trade Partnership Against Terrorism | US. Customs and Border Protection) Audit with 84% score

### Membership of **Associations**

Granules is a member of:



Pharmaceutical Supply Chain Initiative (PSCI)



Bulk Drug Manufacturer Association of India (BDMAI)



Confederation of Indian Industry (CII)



The Federation of Telangana and Andhra Pradesh Chambers of Commerce and Industry (FTAPCCI)



World Economic Forum Center for fourth Industrial Revolution (C4IR) Telangana -Founding Member

#### **Sustainability Ratings**



C Score

Received 'C Score' in Climate Change Disclosure

### ecovadis

### Silver Rating\*

\*Achieved by Unit - 1 Bonthapally

Received EcoVadis Silver Rating for Granules Unit-1 Bonthapally and Bronze Rating for Unit-2 Jeedimetla



Granules MSCI ESG Ratings

#### **Partner Collaboration Platforms**

















